Overview

Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine the optimal treatment conditions (WST11 dose and light energy dose) to achieve ablation in one lobe of the prostate and to evaluate the safety and quality of life of WST11 medicated Vascular-Targeted Photodynamic therapy (VTP) in men with localized prostate cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Steba Biotech S.A.